title: Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
abstract: Insulin sensitizers are attractive candidate therapies for nonalcoholic steatohepatitis mainly because of the strong association between this disease and insulin resistance. This review provides a critical overview of the mechanisms of action, clinical trial results, and safety issues of metformin and glitazones in nonalcoholic steatohepatitis. It also highlights methodological challenges for trial design and proposes endpoints for future proof of principle, registrational, and postmarketing trials.
authors.affiliation: Université Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, Hôpital Pitié Salpêtrière, INSERM UMRS 893 Paris, France. vratziu@teaser.fr
authors.forename: Vlad
authors.initials: V
authors.lastname: Ratziu
authors.forename: Stephen
authors.initials: S
authors.lastname: Caldwell
authors.forename: Brent A
authors.initials: BA
authors.lastname: Neuschwander-Tetri
mesh_terms: D002986:Clinical Trials as Topic; D005234:Fatty Liver / Q000178:diet therapy / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D008687:Metformin / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D008687:Metformin